Corporate Events

Towa Pharmaceutical Co., Ltd. provided consolidated earnings guidance for the six months ending September 30, 2026 and full year ending March 31, 2027. For the six months, the company expects net sales of JPY 145,700 million, operating profit of JPY 12,700 million profit attributable to owners of parent of JPY 8,100 million and earnings per share of JPY 163.02. For the full year, the company expects net sales of JPY 304,000 million, operating profit of JPY 32,000 million, profit attributable to owners of parent of JPY 21,500 million and earnings per share of JPY 430.77.

Towa Pharmaceutical Co., Ltd., Board Meeting, Jul 21, 2026. Agenda: To consider and approve Payment for the Issuance of 1st Series Class A Preferred Shares through Third-Party Allotment and Taking Effect of Reduction of Amounts of Share Capital and Legal Capital Surplus.

Towa Pharmaceutical Co., Ltd., ¥ 40.0, Cash Dividend, Sep-29-2026

Towa Pharmaceutical Co., Ltd. (TSE:4553) signed an agreement to acquire Tanabe Pharma Factory Co., Ltd. from Tanabe Pharma Corporation on July 3, 2026. For the period ending on March 31, 2026, Tanabe Pharma Factory Co., Ltd. reported total revenue of ¥15.8 billion and EBIT of ¥1.1 billion. As of March 31, 2026, Tanabe Pharma Factory Co., Ltd. reported total assets of ¥39.9 billion and total common equity of ¥31.7 billion. The transaction is subject to obtaining antirust clearance. The transaction is expected to complete by the end of November 2026.

Towa Pharmaceutical Co., Ltd., Board Meeting, Jul 03, 2026. Agenda: To consider Acquisition of Shares of Tanabe Pharma Factory Co., Ltd. from Tanabe Pharma Corporation (Making it a Wholly Owned Subsidiary) and Transfer of Manufacturing and Marketing Approvals.

Towa Pharmaceutical Co., Ltd. announced that they will report Q1, 2027 results on Aug 06, 2026

Towa Pharmaceutical Co., Ltd., Board Meeting, Jun 24, 2026. Agenda: To consider and approve the Disposal of Treasury Shares as Restricted Stock Compensation; to consider and approve the Changes in Officers; and to consider and approve other business related matters.

Towa Pharmaceutical Co., Ltd. resolved changes in directors at its Ordinary General Meeting of Shareholders and Board of Directors meeting held on June 24, 2026. Hideshi Nakamura who previously served as Operating Officer, General Manager of President’s Office and in charge of Corporate Strategy Division is appointed as director and Muneya Taniguchi is newly appointed as Outside Director (Audit and Supervisory Committee Member). Hideshi Nakamura is responsible officer under the revised Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices.

Towa Pharmaceutical Co., Ltd. at its Board of Directors meeting held on May 21, 2026 resolved to partially amend the Articles of Incorporation for the establishment of provisions concerning the Class Shares. The Company proposes to amend its Articles of Incorporation to add provisions concerning Class Shares that prescribe them as a new class of shares of the Company in order to enable the Company to issue them. The specifics of the Amendment of the Articles of Incorporation are detailed in Attachment 2, 'Proposed Amendment of the Articles of Incorporation.' The schedule for the Amendment of the Articles of Incorporation is Thursday, May 21, 2026 Board of Directors resolution concerning the Amendment of the Articles of Incorporation, Wednesday, June 24, 2026 Resolution of the 70th Ordinary General Meeting of Shareholders (planned), Effective date of the Amendment of the Articles of Incorporation (planned). The reason for change is to add provisions concerning Class Shares as a new class of shares of the Company in order to enable the Company to issue them.

Towa Pharmaceutical Co., Ltd. Proposed year end dividend for the fiscal year ended March 31, 2026 and provided second quarter end dividend guidance for the fiscal year ending March 31, 2027. For the year end 2026, the company proposed dividend of JPY 40.00 per share against JPY 40.00 per share (Before Split) a year ago. Scheduled date of ordinary general meeting of shareholders: June 24, 2026. Scheduled date to commence dividend payments: June 25, 2026. For the second quarter end 2027, the company expects dividend of JPY 40.00 per share against JPY 40.00 per share a year ago.

Towa Pharmaceutical Co., Ltd. provided consolidated earnings guidance for the six months ending September 30, 2026 and full year ending March 31, 2027. For the six months, the company expects net sales of JPY 145,700 million, operating profit of JPY 12,700 million profit attributable to owners of parent of JPY 8,100 million and earnings per share of JPY 164.54. For the full year, the company expects net sales of JPY 304,000 million, operating profit of JPY 32,000 million, profit attributable to owners of parent of JPY 21,500 million and earnings per share of JPY 436.75.

Towa Pharmaceutical Co., Ltd. provided year end dividend guidance for the fiscal year ending March 31, 2027. for the year end, the company expects dividend of JPY 45.00 per share against JPY 40.00 per share a year ago.

Towa Pharmaceutical Co., Ltd. has entered into an investment agreement with Development Bank of Japan Inc. to issue 10,000 series 1 Class A Preferred Shares at the price of ¥1,000,000 per share for the gross proceeds of ¥10,000,000,000 and 10,000 2nd Series Class A Preferred Shares at the price of ¥1,000,000 per share for the gross proceeds of ¥10,000,000,000 for an total aggregates of ¥20,000,000,000 on May 21, 2026. The transaction has been approved by the board of directors and subject to approval of shareholders which will be held on June 24, 2026. The transaction will happen through Third-party allotment. The company paid issuance fee of ¥127,000,000 and received net proceeds of ¥9,873,000,000 for series 1 shares and issuance fee of up to ¥35,000,000 and received net proceeds of up to ¥9,965,000,000 for series 2 shares on total company will pay ¥162,000,000 received net proceeds of ¥19,838,000,000. The series 1 is expected to close on July 31, 2026 and series 2 is expected to close from August 1, 2026 to April 30, 2027.

Towa Pharmaceutical Co., Ltd., Board Meeting, May 21, 2026. Agenda: To consider Changes in Officers.

Towa Pharmaceutical Co., Ltd., 2026 Earnings Call, May 18, 2026

Towa Pharmaceutical Co., Ltd., Annual General Meeting, Jun 24, 2026.

Towa Pharmaceutical Co., Ltd. announced that they will report fiscal year 2026 results on May 14, 2026

Towa Pharmaceutical Co., Ltd. reported earnings results for the nine months ended December 31, 2025. For the nine months, the company reported sales was JPY 204,065 million compared to JPY 193,737 million a year ago. Net income was JPY 17,082 million compared to JPY 14,624 million a year ago. Basic earnings per share from continuing operations was JPY 347.01 compared to JPY 297.1 a year ago.

Towa Pharmaceutical Co., Ltd. announced that a resolution was passed by the Board of Directors on January 21, 2026 regarding to enter into a basic agreement to establish a strategic collaborative framework for pharmaceutical manufacturing with Otsuka Pharmaceutical Co., Ltd. Through this agreement, the Company and Otsuka Pharmaceutical aim to ensure a stable supply of pharmaceutical products by means of the transfer and contract manufacturing of certain pharmaceutical products owned by Otsuka Pharmaceutical as well as the strategic use of licenses for collaborative products. This basic agreement is intended to address the issue of unstable pharmaceutical supply, which has become a social issue in recent years, and represents a collaborative initiative that transcends the traditional boundaries between brand-name and generic drug companies. The impact of this basic agreement on the Company's consolidated financial results for the fiscal year ending March 2026 is expected to be minimal. However, by leveraging the respective strengths of both companies, the collaboration will contribute to enhancing business performance over the medium to long term.

Towa Pharmaceutical Co., Ltd. expected to report Fiscal Year 2026 results on May 14, 2026. This event was calculated by S&P Global (Created on February 13, 2026).

Towa Pharmaceutical Co., Ltd. announced that they will report Q3, 2026 results on Feb 13, 2026

Towa Pharmaceutical Co., Ltd. announced a cash dividend of JPY 40.00 per share for the second quarter-end of the fiscal year ending March 31, 2026, compared to JPY 30.00 per share paid a year ago. The scheduled date to commence dividend payments is December 1, 2025.

Towa Pharmaceutical Co., Ltd., Q2 2026 Earnings Call, Nov 12, 2025

Towa Pharmaceutical Co., Ltd., ¥ 40.0, Cash Dividend, Mar-30-2026

Towa Pharmaceutical Co., Ltd. expected to report Q3 2026 results on February 13, 2026. This event was calculated by S&P Global (Created on January 16, 2026).